It is a questionable disease in the field of blood tumours, with complex clinical outcomes and often involving multi-system complications. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical outcomes, imaging, laboratory testing and pathological activation.
Platforms can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment. Individualised development of treatment and management of treatment programs for colorectal lung cancer usually includes drug therapy, rehabilitation intervention, and regular follow-up to multidimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved.
Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of colorectal lung cancer. The platform serves the China International Medical Service System, which connects domestic and foreign experts in the field of blood tumours, to provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.